AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan
Jan 30, 2015
- 95 percent SVR12 rate achieved in Japanese patients new to therapy with genotype 1b chronic hepatitis C virus infection without cirrhosis and with a high viral load
- Regulatory filing in Japan planned for the first quarter of 2015
数据来源:
http://www.abbvie.com/